BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Di...
November 25 2019 - 08:30AM
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly
growing commercial-stage specialty pharmaceutical company dedicated
to patients living with chronic conditions, today announced that it
has named Vanila M. Singh, M.D., MACM, to its Board of Directors.
Dr. Singh is currently a Clinical Associate
Professor of Anesthesiology, Pain and Peri-operative Medicine at
Stanford University School of Medicine and is a teaching mentor at
Walter Reed National Military Medical Center. Dr. Singh is
the immediate past Chief Medical Officer of the United States
Department of Health and Human Services (HHS) and served as
Chairperson of the Inter-Agency Pain Management Best Practices Task
Force, chartered by Congress and involving multiple federal health
agencies, professional medical organizations, and patient advocacy
groups to guide the medical community and key stakeholders in
optimal patient care in a growing and complex national health
matter.
“We are very excited and honored to have Dr.
Singh join our organization as a Board member,” stated Peter
Greenleaf, Chairman of BDSI. “Vanila’s profound knowledge and
experience in the fields of molecular science, clinical care,
public health, and matters of national health policy will be
wonderful complements to the significant depth of capabilities
already on our Board and across the organization. Her passion
and national recognition as an ambassador for optimal patient care
blends perfectly with our company’s patient centric culture and
commitment to commercializing clinically differentiated products
with meaningful therapeutic value.”
“Having spent my clinical career and
policy-making leadership focused on improving clinical outcomes
through best practices and patient-centered recommendations, I am
proud to extend my vision by joining BDSI’s Board and to further
deliver solutions that address unmet patient care and focus on
challenges that affect the healthcare system,” added Dr. Singh.
Dr. Singh, board-certified in both
anesthesiology and pain medicine, specializes in treating patients
with complex chronic pain issues. She graduated from the University
of California at Berkeley with a Bachelor of Science degree in both
molecular and cell biology and economics. She received her Medical
degree from the George Washington University School of Medicine
& Health Sciences. Dr. Singh completed her internal medicine
internship at Yale University School of Medicine and her
anesthesiology residency and pain medicine fellowship at
Weill-Cornell New York Presbyterian Hospital, which included
training at Memorial Sloan Kettering and the Hospital for Special
Surgery. She received a master’s degree in academic medicine
through the University of Southern California’s Keck School of
Medicine in 2016. Dr. Singh has been active in various national
medical organizations, having served in the past as the Vice Chair
of the National Physicians Council on Health Policy; an editorial
board member of the Pain Physician Journal for the American Society
of Interventional Pain Physicians; and a member of the California
Medical Association’s (CMA) House of Delegates. She also served on
the CMA’s Council on Ethical, Legal and Judicial Affairs, and more
recently, as a member of its Subcommittee on Health Information
Technology, scientific planning committee of the American Society
of Regional Anesthesia and Pain, and an active member of the
American Society of Anesthesiology. In 2018 she was honored
with a Lifetime Achievement Award by the American Society of
Interventional Pain Physicians.
About BioDelivery Sciences
International, Inc.
BioDelivery Sciences International, Inc.
(NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical
company dedicated to patients living with chronic conditions. BDSI
has built a portfolio of products that includes utilizing its novel
and proprietary BioErodible MucoAdhesive (BEMA®) technology to
develop and commercialize, either on its own or in partnership with
third parties, new applications of proven therapies aimed at
addressing important unmet medical needs. BDSI's marketed products
and those in development address serious and debilitating
conditions such as chronic pain, breakthrough cancer pain, opioid
dependence, and opioid-induced constipation.
Cautionary Note on Forward-Looking
Statements
This press release and any statements of
employees, representatives, and partners of BDSI related thereto
contain, or may contain, among other things, certain
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve significant risks and uncertainties. Such
statements may include, without limitation, statements with respect
to the BDSI’s plans, objectives, projections, expectations and
intentions and other statements identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential” or similar expressions. These statements are based upon
the current beliefs and expectations of the BDSI’s management and
are subject to significant risks and uncertainties, including those
detailed in the BDSI’s filings with the Securities and Exchange
Commission. Actual results may differ materially from those set
forth or implied in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the BDSI’s control) including those set forth in our
2018 annual report on Form 10-K filed with the US Securities and
Exchange Commission and subsequent filings. BDSI undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
© 2019 BioDelivery Sciences International,
Inc. All rights reserved.
Contact:
Tirth T. PatelDirector of Investor
Relationstpatel@bdsi.com(919) 582-0294
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Mar 2023 to Mar 2024